Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
UOX
MCID: URT049
MIFTS: 25

Urate Oxidase, Pseudogene (UOX)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Urate Oxidase, Pseudogene

About this section

MalaCards integrated aliases for Urate Oxidase, Pseudogene:

Name: Urate Oxidase, Pseudogene 56 13
Uricase 56
Uox 56

External Ids:

OMIM 56 191540
Sources

Summaries for Urate Oxidase, Pseudogene

About this section
OMIM : 56 In most mammals, the activity of urate oxidase (EC 1.7.3.3) catalyzes the oxidation of uric acid to allantoin; humans and some primates lack this enzyme activity. The loss of urate oxidase in the human during primate evolution predisposes man to hyperuricemia, a metabolic disturbance that can lead to gouty arthritis and renal stones (summary by Wu et al., 1994). (191540)

MalaCards based summary : Urate Oxidase, Pseudogene, also known as uricase, is related to gout and hyperuricemia. An important gene associated with Urate Oxidase, Pseudogene is UOX (Urate Oxidase (Pseudogene)). The drugs Febuxostat and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and endothelial.

Sources

Related Diseases for Urate Oxidase, Pseudogene

About this section

Diseases related to Urate Oxidase, Pseudogene via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 gout 10.9
2 hyperuricemia 10.9
3 diabetes insipidus, nephrogenic, autosomal 10.2
4 lymphoma, hodgkin, classic 10.2
5 lymphoma, non-hodgkin, familial 10.2
6 diabetes insipidus 10.2
7 burkitt lymphoma 10.1
8 hepatocellular carcinoma 10.1
9 nephrolithiasis, calcium oxalate 10.1
10 wilms tumor 5 10.1
11 hyperglycemia 10.1
12 uremia 10.1
13 severe combined immunodeficiency 10.1
14 fatty liver disease 10.1
15 rapidly involuting congenital hemangioma 10.1

Graphical network of the top 20 diseases related to Urate Oxidase, Pseudogene:



Diseases related to Urate Oxidase, Pseudogene
Sources

Symptoms & Phenotypes for Urate Oxidase, Pseudogene

About this section

Clinical features from OMIM:

191540
Sources

Drugs & Therapeutics for Urate Oxidase, Pseudogene

About this section

Drugs for Urate Oxidase, Pseudogene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Febuxostat Approved Phase 4 144060-53-7 134018
2
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
3
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
6
Norethindrone Approved Phase 4 68-22-4 6230
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
11
Uric acid Investigational Phase 4 69-93-2 1175
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Antirheumatic Agents Phase 4
14 Antioxidants Phase 4
15 Protective Agents Phase 4
16 Pharmaceutical Solutions Phase 4
17 Giapreza Phase 4
18 Angiotensinogen Phase 4
19 Vitamins Phase 4
20 Antihypertensive Agents Phase 4
21 Tocopherols Phase 4
22 Tocotrienols Phase 4
23 Lecithin Phase 4
24 Silybin Phase 4
25 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
26 insulin Phase 4
27 Insulin, Globin Zinc Phase 4
28 Estrogens Phase 4
29 HIV Protease Inhibitors Phase 4
30
protease inhibitors Phase 4
31 Natriuretic Agents Phase 4
32 Norethindrone Acetate Phase 4
33 Estradiol 17 beta-cypionate Phase 4
34 Contraceptive Agents Phase 4
35 Hormone Antagonists Phase 4
36 Sodium Chloride Symporter Inhibitors Phase 4
37 Angiotensin-Converting Enzyme Inhibitors Phase 4
38 Contraceptives, Oral Phase 4
39 Hormones Phase 4
40 Progestins Phase 4
41 diuretics Phase 4
42 Estradiol 3-benzoate Phase 4
43
Allopurinol Approved Phase 2 315-30-0 2094
44
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
45
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
46
Rasburicase Approved, Investigational Phase 1 134774-45-1

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
2 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
3 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
4 Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00325195 Phase 3
5 Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout Completed NCT01356498 Phase 3
6 A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout Completed NCT00111657 Phase 2
7 An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid Completed NCT02959918 Phase 2 SEL-212;SEL-037;SVP-rapamycin (SEL-110)
8 A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy Recruiting NCT03905512 Phase 2 SEL-212;SEL-037;SEL-110;KRYSTEXXA®
9 ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D Not yet recruiting NCT03899883 Phase 2 Pegloticase 8 MG/ML [Krystexxa]
10 A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20 Unknown status NCT01038947 Phase 1
11 A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20 Unknown status NCT01021241 Phase 1
12 An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels Completed NCT02464605 Phase 1
13 A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid Completed NCT02648269 Phase 1 SEL-110
14 The Relationship Between Uric Acid and Inflammatory Markers Completed NCT01323335 Phase 1 IV Uric Acid;IV Rasburicase
15 A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers. Recruiting NCT03388515 Phase 1
16 An Open Label, Single-dose, Dose-increasing Study to Assess the Safety, Tolerability, PK and Preliminary PD of PEGylated Recombinant Candida Urate Oxidase (SSS11) for Injection in Chinese Healthy Adult Volunteers Not yet recruiting NCT04047394 Phase 1 PEGylated recombinant candida urate oxidase
17 Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension Unknown status NCT01523327
18 Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress Recruiting NCT03395977 Placebos;Febuxostat;Rasburicase
19 Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage Active, not recruiting NCT03169257

Search NIH Clinical Center for Urate Oxidase, Pseudogene

Sources

Genetic Tests for Urate Oxidase, Pseudogene

About this section
Sources

Anatomical Context for Urate Oxidase, Pseudogene

About this section

MalaCards organs/tissues related to Urate Oxidase, Pseudogene:

40
Liver, Kidney, Endothelial, Testes, Brain, Heart, Retina
Sources

Publications for Urate Oxidase, Pseudogene

About this section

Articles related to Urate Oxidase, Pseudogene:

(show top 50) (show all 1031)
# Title Authors PMID Year
1
Evolutionary history and metabolic insights of ancient mammalian uricases. 61 56
24550457 2014
2
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. 61 56
8290593 1994
3
Structural analysis of the gene encoding rat uricase. 61 56
1783398 1991
4
Urate oxidase: primary structure and evolutionary implications. 61 56
2594778 1989
5
A human genomic sequence highly homologous to the 3'-untranslated region of rat uricase mRNA. 61 56
3178807 1988
6
Localization of the human urate oxidase gene (UOX) to 1p22. 56
1395718 1992
7
Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. 56
2403354 1990
8
Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase. 56
3344434 1988
9
A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. 56
3029599 1987
10
HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. 56
3821905 1987
11
Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 56
13937884 1962
12
Electrochemical determination of uric acid in urine and serum with uricase/carbon nanotube /carboxymethylcellulose electrode. 61
31836385 2020
13
Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. 61
31996020 2020
14
Hypouricemia: what the practicing rheumatologist should know about this condition. 61
31650389 2020
15
Brushing the surface: cascade reactions between immobilized nanoreactors. 61
31859312 2020
16
Establishment of high HPRT activity-Uox KO mice to test the pharmacological effects of purine and non-purine type xanthine oxidoreductase inhibitors. 61
31971609 2020
17
Enhanced Performance of Reagent-Less Carbon Nanodots Based Enzyme Electrochemical Biosensors. 61
31861148 2019
18
Development of Uric Acid Biosensor Biosensor using Gold Nanoparticles and Graphene Oxide Functionalized Micro-Ball Fiber Sensor Probe. 61
31831430 2019
19
Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study. 61
31752638 2019
20
Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices. 61
31673974 2019
21
Potential of a sensitive uric acid biosensor fabricated using hydroxyapatite nanowire/reduced graphene oxide/gold nanoparticle. 61
31729094 2019
22
A ratiometric fluorescent probe for detection of uric acid based on the gold nanoclusters-quantum dots nanohybrid. 61
31176998 2019
23
Uricase-containing coacervate microdroplets as enzyme active membrane-free protocells for detoxification of uric acid in serum. 61
31675031 2019
24
A dual-signal colorimetric and ratiometric fluorescent nanoprobe for enzymatic determination of uric acid by using silicon nanoparticles. 61
31705210 2019
25
Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: A comparative 26-week toxicity study in rats and monkeys. 61
31610209 2019
26
Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. 61
31621967 2019
27
Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy. 61
31253939 2019
28
The value of serum uric acid levels to differentiate causes of transient loss of consciousness. 61
31476728 2019
29
Application of cyclic voltammetry to analyse uric acid and reducing agents in commercial milks. 61
31151606 2019
30
Screening of single or combined administration of 9 probiotics to reduce ammonia emissions from laying hens. 61
30982063 2019
31
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4. 61
31506445 2019
32
Fabrication of an efficient and sensitive colorimetric biosensor based on Uricase/ Th-MOF for uric acid sensing in biological samples. 61
31220726 2019
33
Toxicity assessment of wearable wound sensor constituents on keratinocytes. 61
30928693 2019
34
Antioxidant capacities in various animal sera as measured with multiple free-radical scavenging method. 61
31272792 2019
35
Nanozymes: From New Concepts, Mechanisms, and Standards to Applications. 61
31276379 2019
36
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. 61
31079535 2019
37
Mouse models for human hyperuricaemia: a critical review. 61
31118497 2019
38
Serum Urate, Uricase, and Blood Pressure Control in Gout. 61
31079534 2019
39
Uricase grafted nanoconducting matrix based electrochemical biosensor for ultrafast uric acid detection in human serum samples. 61
30797811 2019
40
A nanocomposite prepared from copper(II) and nitrogen-doped graphene quantum dots with peroxidase mimicking properties for chemiluminescent determination of uric acid. 61
31161235 2019
41
Uricase and Horseradish Peroxidase Hybrid CaHPO₄ Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia. 61
30890227 2019
42
Statistical media optimization for the production of clinical uricase from Bacillus subtilis strain SP6. 61
31193400 2019
43
Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis. 61
30690853 2019
44
Association between Serum Uric Acid Level with Presence and Severity of Coronary Artery Disease. 61
31311215 2019
45
Uric acid therapy for vasculoprotection in acute ischemic stroke. 61
31334357 2019
46
Advanced Colorimetric Paper Sensors Using Color Focusing Effect Based on Asymmetric Flow of Fluid. 61
30950270 2019
47
Potential Dangers of Serum Urate-Lowering Therapy. 61
30611833 2019
48
Uric acid analogue as a possible xenobiotic marker of uric acid transporter Urat1 in rats. 61
30826184 2019
49
Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment. 61
30986917 2019
50
Pharmacological urate-lowering approaches in chronic kidney disease. 61
30769179 2019
Sources

Variations for Urate Oxidase, Pseudogene

About this section
Sources

Expression for Urate Oxidase, Pseudogene

About this section
Search GEO for disease gene expression data for Urate Oxidase, Pseudogene.
Sources

Pathways for Urate Oxidase, Pseudogene

About this section
Sources

GO Terms for Urate Oxidase, Pseudogene

About this section
Sources

Sources for Urate Oxidase, Pseudogene

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....